Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Junghyun Cho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Albuminuria, Glucosides, Biomarkers. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ministry of Science and Technology Information and Communication, Medical Research Center, Soonchunhyang University Research Fund.
Abstract (Originalsprache)
The beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) with low albuminuria levels have not been established. This study aimed to compare the effects of dapagliflozin on kidney injury biomarkers in patients with CKD stratified by albuminuria level. We prospectively enrolled healthy volunteers (HVs; n = 20) and patients with CKD ( n = 54) with and without diabetes mellitus. Patients with CKD were divided into two age‐matched and sex‐matched subgroups according to urinary albumin–creatinine ratio (uACR) levels (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, Korea.
- Department of Urology, Soonchunhyang University Seoul Hospital, Seoul, Korea.
- Hyonam Kidney Laboratory, Soonchunhyang University Seoul Hospital, Seoul, Korea.
ORCID-Profile: Junghyun Cho, Seung Whan Doo, Nayoung Song, Minsul Lee, Haekyung Lee, Hyongnae Kim, Jin Seok Jeon, Hyunjin Noh, Soon Hyo Kwon
Förderung
- Ministry of Science and Technology Information and Communication
- Medical Research Center
- Soonchunhyang University Research Fund
Zitieren
APA
Cho, J., Doo, S. W., Song, N., Lee, M., Lee, H., Kim, H., Jeon, J. S., Noh, H., & Kwon, S. H. (2024). Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3237
Vancouver
Cho J, Doo SW, Song N, Lee M, Lee H, Kim H, et al. Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3237
BibTeX
@article{Cho2024,
author = {Cho, Junghyun and Doo, Seung Whan and Song, Nayoung and Lee, Minsul and Lee, Haekyung and Kim, Hyongnae and Jeon, Jin Seok and Noh, Hyunjin and Kwon, Soon Hyo},
title = {Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3237}
}
EUVIMED